TP53 and neoplasm: Leon-Castillo et al. reported on ECs that have more than one molecular feature.83 They demonstrated that tumours with a pathogenic mutation in POLE that also have MMRd and/or mutations in TP53, have morphology, molecular profiles and clinical behaviour aligning with POLEmut EC.